Key Takeaways
-
Johnson & Johnson plans to acquire Ollin Biosciences for $2.2 billion upfront, plus milestone payments
-
OLN324 is an investigational bispecific antibody targeting VEGF and Ang2, with the potential to improve retinal fluid control and extend treatment intervals in wet AMD and DME
-
Blackstone Life Sciences will provide $750 million to fund phase 3 development of OLN324, contingent upon the acquisition closing
Johnson & Johnson has entered into a definitive agreement to acquire Ollin Biosciences for $2.2 billion upfront, with additional potential milestone payments of up to approximately $1.1 billion, expanding its ophthalmology pipeline with an investigational therapy for retinal diseases.
The acquisition would add OLN324, a bispecific antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), to Johnson & Johnson's portfolio. The therapy is being developed for wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
According J&J, OLN324 features high Ang2 potency and a small protein format, known as a minibody, designed to potentially improve retinal fluid control and extend treatment intervals.
“OLN324 selectively targets two important drivers of retinal disease and has the potential to achieve stronger and more sustained disease control,” said Kip Connor, Vice President, Ophthalmology Disease Area Stronghold Leader, Johnson & Johnson. “The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients.”
Under a separate development funding agreement, Blackstone Life Sciences will provide $750 million over multiple years to fully fund the phase 3 clinical development of OLN324, contingent upon completion of the acquisition. In exchange, Blackstone will be eligible for certain regulatory and sales milestone payments and single-digit royalties.
In June, Ollin Biosciences closed an oversubscribed $330 million Series B financing round to fund global phase 3 development of OLN324 as well as support the advancement of OLN102, a TSHR/IGF-1R bispecific antibody for thyroid eye disease (TED) and Graves’ disease, into clinical development.
The acquisition is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions.